Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Canbridge PharmaceuticalsHKSE:01228 +2.50%48 Current Ratio is 0.24 as of Dec. 2025, which is 72% below its 10-year median of 0.87. GuruFocus rates HKSE:01228 with a GF Score™ of 48/100 and a GF Value™ of HK$0.38 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,410 Biotechnology companies, Canbridge Pharmaceuticals ranks worse than 94.61% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Canbridge Pharmaceuticals's current ratio for the quarter that ended in Dec. 2025 was 0.24.
Canbridge Pharmaceuticals has a current ratio of 0.24. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Canbridge Pharmaceuticals has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Canbridge Pharmaceuticals's Current Ratio or its related term are showing as below:
HKSE:01228'
s Current Ratio Range Over the Past 10 Years
Min: 0.09 Med: 0.87 Max: 4.37
Current: 0.24
During the past 7 years, Canbridge Pharmaceuticals's highest Current Ratio was 4.37. The lowest was 0.09. And the median was 0.87.
HKSE:01228's Current Ratio is ranked worse than 94.61% of 1410
companies
in the Biotechnology industry
Industry Median: 3.88
vs HKSE:01228: 0.24
Canbridge Pharmaceuticals (HKSE:01228) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Canbridge Pharmaceuticals Current Ratio Related Terms
Canbridge Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01228 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Canbridge Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canbridge Pharmaceuticals Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Canbridge Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Canbridge Pharmaceuticals (HKSE:01228) has a Current Ratio of 0.24 as of Dec. 2025. This is 72% below median its historical median of 0.87. Over the past decade, Canbridge Pharmaceuticals' Current Ratio has ranged from 0.09 to 4.37. According to the industry distribution chart, Canbridge Pharmaceuticals ranks #1334 out of 1410 companies in the Biotechnology industry, placing it in the top 94.6%.
Is Canbridge Pharmaceuticals' Current Ratio too high?
Canbridge Pharmaceuticals' current Current Ratio of 0.24 is 72% below median its 10-year median of 0.87. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 4.37. The Biotechnology industry median Current Ratio is 3.88. Canbridge Pharmaceuticals' value of 0.24 is 93.8% below this industry median. Based on the distribution chart, Canbridge Pharmaceuticals ranks #1334 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Canbridge Pharmaceuticals has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canbridge Pharmaceuticals' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Canbridge Pharmaceuticals ranks #1334 out of 1410 companies for Current Ratio. This places Canbridge Pharmaceuticals in the lower half of its industry. The industry median Current Ratio is 3.88. Canbridge Pharmaceuticals' value of 0.24 is 93.8% below this benchmark. Historically, Canbridge Pharmaceuticals' own Current Ratio has ranged from 0.09 to 4.37 over the past decade. While the company's 10-year median is 0.87 vs. the industry median of 3.88, Canbridge Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Canbridge Pharmaceuticals's current Current Ratio of 0.24 is 93.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Canbridge Pharmaceuticals's current Current Ratio is 0.24, which is 72% below median its own 10-year median of 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canbridge Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Canbridge Pharmaceuticals (HKSE:01228) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.38, compared to a current price of HK$2.05 — trading 439.5% above its estimated fair value. The current Current Ratio is 0.24, which is 72% below median its 10-year median of 0.87 and 93.8% below the Biotechnology industry median of 3.88. Canbridge Pharmaceuticals' overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Canbridge Pharmaceuticals (HKSE:01228), the current Current Ratio is 0.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canbridge Pharmaceuticals (HKSE:01228) Overvalued in 2026?
Based on GuruFocus' analysis, Canbridge Pharmaceuticals stock appears to be overvalued.
The current stock price of HK$2.05 is trading 439.5% above its estimated GF Value™ of HK$0.38.
GuruFocus considers Canbridge Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for HKSE:01228:
Current Ratio: 0.24 (72% below median its 10-year median of 0.87)
GF Value™: HK$0.38 vs. price of HK$2.05 (439.5% above fair value)
Industry Position: 93.8% below the Biotechnology median (#1334 of 1410)
No single metric tells the full story. See the HKSE:01228 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.
48GF Score
Get the complete analysis for HKSE:01228
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01228 has been successfully added to your 
